MALVERN, Pa., Nov. 2, 2010 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that the leading driver of antibiotic selection in nosocomial pneumonia in the United States is activity against key drug-resistant pathogens. Such pathogens include P. aeruginosa, MRSA, Vancomycin-resistant Staphylococcus aureus and multidrug-resistant Steptococcus pneumonia.
"Nosocomial pneumonia is one of the most important indications for hospital antibiotics in the U.S. because of its relatively high morbidity and mortality and high frequency of drug-resistant pathogens," stated James Andersen, analyst at AMR.
In the new report entitled Hospital Anti-Infectives Insight Series: Nosocomial Pneumonia, surveyed physicians indicate that the excellent bactericidal activity and lung penetration of Pfizer's Zosyn are primary reasons for its success in the nosocomial pneumonia drug market, while Pfizer's success with Zyvox is largely driven by its convenient availability in a dual IV/oral formulation. Johnson & Johnson's success with Levaquin is driven by a high level of experience among surveyed physicians, relatively high activity against nosocomial pneumonia pathogens, low dosing frequency and dual IV/oral formulation.
About the Report
AMR's Hospital Anti-Infectives Insight Series: Nosocomial Pneumonia analyzes hospital antibiotic prescribing patterns using AMR's comprehensive and highly detailed clinical data in conjunction with primary research and extensive understanding of emerging therapies and forecasts. This report contains U.S. data and examines the reasons behind physicians' product preferences, factors driving hospital antibiotic prescribing patterns and receptivity to emerging antibiotics.
AMR (www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com .
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
|SOURCE Arlington Medical Resources|
Copyright©2010 PR Newswire.
All rights reserved